Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in: Drugs & Therapy Perspectives 1/2006

01-01-2006 | Disease Management

Pharmacotherapy for the treatment of obesity has only modest benefits and should be used in combination with lifestyle modifications

Published in: Drugs & Therapy Perspectives | Issue 1/2006

Login to get access

Excerpt

Pharmacotherapy to reduce obesity is only considered an appropriate adjunctive option for patients with a severe weight problem who have failed to lose weight by a reasonable trial of other means (diet and/or lifestyle alterations). Only a few pharmacotherapies are currently approved for the management of weight loss. Safety issues have resulted in many therapies being withdrawn or having limited availability. The only two drugs approved for long-term use are sibutramine and orlistat. Both result in modest weight loss over periods of 1–2 years and appear to have reasonable safety profiles. …
Literature
1.
Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005; 65(10): 1391–418PubMedCrossRef
2.
3.
National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. NIH Publication no. 98-4083. Washington, DC: US Government Press, 1998 Sep
4.
Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005 Nov 17; 353(20): 2111–20PubMedCrossRef
5.
Munro JF, MacCuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968; 1: 352–4PubMedCrossRef
6.
Truant AP, Olon LP, Cobb S. Phentermine resin as an adjunct in medical weight reduction: a controlled, randomized, double-blind prospective study. Curr Ther Res Clin Exp 1972; 14: 726–38PubMed
7.
Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289: 1537–45PubMedCrossRef
8.
US Food and Drug Administration. Dietary supplements containing ephedrine alkaloids: final rule summary [online]. Available from URL: http://​www.​fda.​gov[Accessed 2005 Oct 12]
9.
Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293: 2873–83PubMedCrossRef
10.
Aydin N, Topsever P, Kaya A, et al. Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients? Tohoku J Exp Med 2004; 202: 173–80PubMedCrossRef
11.
Wadden TA, Berkowitz RI, Womble LG, et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 6: 431–7CrossRef
12.
13.
Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; 3: CD004094PubMed
14.
Hauner H, Meier M, Jockel KH, et al. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein β3 subunit gene (GNB3) C825T polymorphism. Pharmacogenetics 2003; 13: 453–9PubMedCrossRef
15.
Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116–23PubMedCrossRef
16.
McMahon FG, Weinstein SP, Rowe E, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 2002; 16: 5–11PubMedCrossRef
17.
McMahon FG, Fujioka K, Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160(14): 2185–91PubMedCrossRef
18.
Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–61PubMedCrossRef
19.
Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002; 10: 1049–56PubMedCrossRef
20.
Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002; 10: 633–41PubMedCrossRef
21.
Goldstein DJ, Rampey AH Jr, Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994; 18: 129–35PubMed
22.
Darga LL, Carroll-Michals L, Botsford SJ, et al. Fluoxetine’s effect on weight loss in obese subjects. Am J Clin Nutr 1991; 54: 321–5PubMed
23.
Griffen L, Anchors M. The “Phen-Pro” diet drug combination is not associated with valvular heart disease. Arch Intern Med 1998; 158: 1278–9PubMedCrossRef
24.
Gadde KM, Franciscy DM, Wagner II HR, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289: 1820–5PubMedCrossRef
25.
VanGaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–97PubMedCrossRef
Metadata
Title
Pharmacotherapy for the treatment of obesity has only modest benefits and should be used in combination with lifestyle modifications
Publication date
01-01-2006
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 1/2006
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.2165/00042310-200622010-00003

Other articles of this Issue 1/2006

Drugs & Therapy Perspectives 1/2006 Go to the issue

Disease Management

Ensure adequate and individualised symptomatic pain treatment of HIV-associated distal symmetrical polyneuropathy

Product Introductions

New in the marketplace

Drug Reactions and Interactions

First reports of adverse drug reactions in recent weeks

Drug and Profile Reports

Imiquimod in superficial basal cell carcinoma: profile report

Disease Management

Treatment of gouty arthritis requires both immediate action and long-term strategies to put out the ‘fire’

Drug and Profile Reports

Eplerenone reduces deaths from heart failure after a heart attack and effectively treats hypertension